ArticleJournal of extracellular vesicles2021
Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients.
Article in Journal of extracellular vesicles, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Beyond hemostasis, the immunomodulatory nature of platelets.Research and practice in thrombosis and haemostasis · 2025Review
- Assessing Extracellular Vesicle Turnover In Vivo Using Highly Sensitive Phosphatidylserine-Binding Reagents.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Extracellular vesicle surface display enhances the therapeutic efficacy and safety profile of cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Platelet and Monocyte Microvesicles as Potential Biomarkers of COVID-19 Severity: A Cross-Sectional Analysis.Annals of laboratory medicine · 2024Article
- New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology.Pharmaceuticals (Basel, Switzerland) · 2024Review
- CD66bJournal of extracellular vesicles · 2024Article
- Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Phosphatidylserine-positive extracellular vesicles boost effector CD8Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Phosphatidylserine-Exposing Annexin A1-Positive Extracellular Vesicles: Potential Cancer Biomarkers.Vaccines · 2023Article
- The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury.Frontiers in cardiovascular medicine · 2023Review
- Exploring Urinary Extracellular Vesicles and Immune Mediators as Biomarkers of Kidney Injury in COVID-19 Hospitalized Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Serum-derived extracellular vesicles: Novel biomarkers reflecting the disease severity of COVID-19 patients.Journal of extracellular vesicles · 2022Article
- The Role of Platelet-Derived Extracellular Vesicles in Immune-Mediated Thrombosis.International journal of molecular sciences · 2022Review
- Procoagulant platelet sentinels prevent inflammatory bleeding through GPIIBIIIA and GPVI.Blood · 2022Article
- Platelet and extracellular vesicles in COVID-19 infection and its vaccines.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Review
- Platelet-Released Factors: Their Role in Viral Disease and Applications for Extracellular Vesicle (EV) Therapy.International journal of molecular sciences · 2022Review
- The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors.Frontiers in immunology · 2022Review
- Persistent Lung Injury and Prothrombotic State in Long COVID.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
Abstract
Infection with SARS-CoV-2 is associated with thromboinflammation, involving thrombotic and inflammatory responses, in many COVID-19 patients. In addition, immune dysfunction occurs in patients characterised by T cell exhaustion and severe lymphopenia. We investigated the distribution of phosphatidylserine (PS), a marker of dying cells, activated platelets and platelet-derived microparticles (PMP), during the clinical course of COVID-19. We found an unexpectedly high amount of blood cells loaded with PS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.